David A. Hyman, MD, JD, on Inclusive Shared Savings

Mark J. Ratain, MD, of the University of Chicago, talks about why ibrutinib—which can lead to cardiotoxicities—should be studied at a lower dose for patients with chronic lymphocytic leukemia. Data suggest a reduced dose may prevent dose interruption due to adverse events and may have a better therapeutic index.

Cost of Care

The ASCO Post Staff

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Cutting Cancer Care Costs With Alternative Pharmacologic Options

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, of Emory University, discusses the ways in which clinical pharmacology can help yield cost savings without sacrificing efficacy by, for example, altering regimens to extend drug supplies, lowering doses, dosing less frequently, or shortening the duration of treatment.

David A. Hyman, MD, JD, on Inclusive Shared Savings

Related Videos

Ian Tannock, MD, PhD, DSc, on Near-Equivalence: A Better Question Than Non-Inferiority

Mark J. Ratain, MD, on Chronic Lymphocytic Leukemia: Making a Case for Low-Dose Ibrutinib

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Cutting Cancer Care Costs With Alternative Pharmacologic Options

Robin Feldman, JD: Are Dubious Patents a Large or Small Issue?

Leonard B. Saltz, MD, on the Future of Interventional Pharmacoeconomics

Renowned Breast Cancer Physician-Scientist to Lead Womens Cancers Program at City of Hope

Poor Agreement Reported Among Diagnostic Tests for Breast Cancer Related Lymphedema

How Does Medicaid Expansion Affect Access to Care in Patients With NSCLC

Advanced Esophageal Cancer NOTCH1 Mutation and Efficacy of Immunotherapy

Dual Use of Cigarettes and E-Cigarettes on Par With Sole Cigarette Use in Terms of Toxic Exposure